Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Arrowhead Pharmaceuticals Inc.
DescriptionShort interfering RNAs targeting 2 regions of the HBV genome conjugated to N-acetylgalactosamine-polymer and cholesterol ligands using Arrowhead's Dynamic Polyconjugate delivery system
Molecular Target
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA: siRNA
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis B virus (HBV)
Indication DetailsTreat chronic HBV infection; Treat HBV infection
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today